Blocking the PD-1/PD-L1 interaction with anti-PD-L1 therapeutic agents prevents the deactivation of CD8+ T-cells (Figure 2) and enhances the immune response against cancer cells, leading to tumour regression [64]. Here, CD274 is linked to neoplasm.